![119021558 119021558](https://api.time.com/wp-content/uploads/2015/02/119021558.jpg?quality=85&w=2400)
By David Stout
The U.S. Food and Drug Administration has allowed Google-backed company 23andMe to begin marketing a home genetic test for Bloom Syndrome — an inherited condition characterized by shortness of height and increased risk of cancer.
The FDA also announced that it intends to exempt similar genetic testing devices from its premarket review protocol.
Screening tests are largely used by prospective parents who are concerned that their future children may inherent harmful genetic disorders.
“Today’s authorization … along with FDA’s intent to exempt these devices from FDA premarket review, supports innovation and will ultimately benefit consumers” stated spokesman Alberto Gutierrez.
More Must-Reads from TIME
- Welcome to the Noah Lyles Olympics
- Melinda French Gates Is Going It Alone
- What to Do if You Can’t Afford Your Medications
- How to Buy Groceries Without Breaking the Bank
- Sienna Miller Is the Reason to Watch Horizon
- Why So Many Bitcoin Mining Companies Are Pivoting to AI
- The 15 Best Movies to Watch on a Plane
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time
Contact us at letters@time.com